IOVANCE BIOTHERAPEUTICS, INC. (IOVA): Investor presentation

Iovance Biotherapeutics (IOVA) reported a 50% response rate in a trial of its lifileucel therapy for metastatic sarcoma, with four ongoing partial responses. The trial involved eight patients with prior treatments, and the safety profile matched other indications. The FDA granted fast track designation for lifileucel in Q2 2026. Iovance is conducting a Phase 2 trial with a primary endpoint of objective response rate.

Iovance Biotherapeutics reported phase 2 data showing a 62.5% objective response rate and 29.2% complete response rate for Amtagvi combined with Merck's Keytruda in first-line melanoma patients. The data was presented at a medical conference.

Iovance Biotherapeutics (IOVA) reported final Phase 2 results for lifileucel plus pembrolizumab in frontline advanced melanoma, showing 62.5% ORR and 29.2% CR, with median OS not reached at 50.9 months. The data was presented at ESMO Congress 2026, supporting ongoing Phase 3 trial TILVANCE-301. The company estimates 70,000 addressable patients annually in global markets. Safety was consistent with known profiles.

Iovance reported Phase 2 data showing 62.5% ORR and 29.2% CR for lifileucel plus pembrolizumab in frontline advanced melanoma. Median OS not reached at 50.9 months' follow-up. The results support a potential shift to frontline use, aligning with Phase 3 strategy.

Iovance Biotherapeutics (IOVA) announced that its lifileucel combined with pembrolizumab showed promising results in a Phase 2 trial for frontline advanced melanoma. The study reported a median progression-free survival of 19.8 months, with median overall survival not reached at over 4 years. The company is conducting a Phase 3 trial (TILVANCE-301) to support potential approval for this combination therapy. Iovance estimates a global market of 70,000 patients annually for this indication.

Iovance Biotherapeutics [IOVA] reported Q2 2026 revenue of $99.3m, raising full-year guidance to $410m-$420m. Its FDA-approved TIL therapy, Amtagvi, faces logistical challenges but shows commercial momentum. IOVA stock surged 28% post-guidance upgrade, up 433% YTD. Competitors include Immunocore [IMCR] and Bristol-Myers Squibb [BMY].